Home --------------SOURCING OF ORGANIC COMPOUNDS


SOURCING OF ORGANIC COMPOUNDS

Follow amcrasto on Twitter  KEEO IN TOUCH WITH ME


the lady

site for SOURCING OF ORGANIC COMPOUNDS used in organic synthesis, part of main page shown below





PAGE CREATED BY DR ANTHONY MELVIN CRASTO M.SC, PH.D (ORGANIC CHEMISTRY,23+ years experience in the field of research and development
email  amcrasto@gmail.com

View Larger Map    GLENMARK RESEARCH CENTRE
MY RESEARCH CENTRE AT NAVI MUMBAI INDIA

Ентоні  アンソニー  Αντώνιος  安东尼    แอนโทนี   Энтони   אַנטאַני  Антхони  एंथनी  안토니  أنتوني


LINKS, WLL B UPDATED


DEVELOPING AND IMPLEMENTING A STRATEGIC SOURCING STRATEGY -


This site is optimized for the features of:

Netscape Navigator

 

Microsoft Internet Explorer

 i

 




   Search Britannica.com

Top of Form

PicoSearch



Note: The Pico Search service is supported by banner advertisement. My use of this service does not constitute endorsement of any services or products advertised.

Bottom of Form





cid:_1_08EB9CDC08EB996C00471C786525773FHow Are Purchasing & Sourcing Different Today?

The new year's arrival made me ponder how purchasing is ///. Here are the top 10 purchasing changes in those 10 years. 

10. Technology Proliferated. Today, eProcurement and eSourcing are two of the most useful practices in purchasing. Ten years ago, those terms were unheard of. 

9. Center-Led Procurement Arrived. In 1998, even top purchasing departments processed purchase orders. Today, purchasing departments aim to centralize the supplier selection process, not transactions, which are delegated to end users or outsourced. 

8. Purchasing Grabbed More Spend. When purchasing departments deliver results, management seeks more spend that Purchasing can positively impact. Once sourced by other departments, categories like fleet management, benefits, and travel services are now sourced by Purchasing. 

7. Social Responsibility Became A Top Priority. Whether for philanthropy or to avoid media scandals, management counts on Purchasing more than ever to buy from diverse suppliers, make environmentally-conscious decisions, and do business ethically. 

6. Measurement Was Mandated. With the potential of smart purchasing widely known, senior management more strictly holds their purchasing departments accountable for results. The use of purchasing metrics and dashboards is now commonplace. 

5. Strategic Sourcing Went DIY. In the '90's, strategic sourcing was done mostly by consulting firms hired to help companies reduce spend. Today, many companies have their own refined and documented in-house strategic sourcing processes. 

4. Supplier Roles Expanded. In 1998, there was talk about "partnering" with suppliers. Today, there's action. Top purchasing departments actively develop their suppliers and look to the supply base for ideas, better performance, and innovation. 

3. Global Sourcing Went Mainstream. Ten years ago, only the progressive companies were searching abroad for suppliers. Now, in some countries, it is difficult to find products manufactured domestically. 

2. The CPO Position Got Adopted. This past year alone, I've encountered an unprecedented number of folks with the title "Chief Procurement Officer." 

1. The Supply Chain Was Recognized. In the last decade, companies more closely analyzed the way material flows into, through, and out of the organization. This "supply chain" focus has those who once just placed orders now responsible for inventory, warehousing, outbound logistics, and distribution.




Innovative Sourcing Strategies

The efficient allocation of capital, particularly in the “make or buy” decision, has the power to
increase earnings and shareholder value. The state of  the pharmaceutical industry makes strategic
sourcing decisions more important and more urgent than ever.  What are the benefits and possible
problems inherent in sourcing, and what are the best ways to innovate and implement a sourcing
strategy?
The choices that leaders of pharmaceutical companies make in the allocation and management of
capital have the power to increase shareholder value, improve profitability, provide the resources to
fund strategic investments internally, and shorten response time and customer service.
Potential performance improvements like these are welcome at a time when pharmaceuticals are
struggling to maintain profit and growth scenarios, greater market competition, and increased
pressure from both society and government on their R&D pipelines, and to deliver healthcare
solutions at lower costs.
Strategic sourcing and supply management offers wise managers one of the powerful opportunities to
extract cash from the value chain and set the stage for continued product and service innovation and
growth. The key to unlocking the value in sourcing rests with an understanding of efficient capital
management. Capital drives everything. When the major players in the pharmaceutical industry were
generating strong positive cash flows, capital was not an issue. Now, however, to maintain acceptable
margins, these companies must run at a leaner pitch. This imperative for leaner operations added to
escalating cost pressures and the emergence of capable new manufacturing sources demands that
pharmaceutical companies now re-evaluate their in-house manufacturing operations.
Even if companies continue to do all, or just part of their manufacturing in-house-for proprietary,
quality, competitive, or even ‘insurance’ reasons, the potent combination of market forces has
already begun to change the rules of the game.









Typically, companies are willing to pay what amounts to a premium for in-house manufacturing,
particularly in the critical launch phase of a new product. However, as the product matures, the
market may very  well accept these premiums.
The entrepreneurial biotechnology companies, for reasons of necessity, have already adopted
progressive sourcing strategies, and their example is serving as a wake-up call to companies with
traditional in-house manufacturing operations.
Capital and other cost pressures
After more than a decade of mergers, acquisitions, restructuring, and fundamental changes in the basis
of competition, our experience suggests that in-house pharmaceutical manufacturing operations are
often under-used, and burdened with overhead costless efficient than external alternatives. Some
drug makers are starting to see their in-house operations as non-core contributors to their overall
business performance.
Underlying the  wake up call is the experience of the 1970s, during which the FDA and European
Regulatory agencies understandably added essential requirements and controls. Pharmaceutical
companies responded with capital-laden facilities together with over-designed and over-demanding
business processes and policies relative to audit, assurance, regulatory and manufacturing functions.
Some of the companies proudly established policies and control procedures exceeding regulatory
agencies’ requirements, winning the hearts of the medical community. A deeply rooted culture of
delivering higher standards through bureaucratic operating procedures has grown and it is difficult to
change as these policies and procedures are perceived as threshold requirements in the face of growing
capital, cost and other competitive challenges.
During the high-growth, high-return days of the 1980s and eaarly 1990s, these basic business flaws
were easily absorbed in most companies’ bottom lines. Today, however, the changing power structure
in managed care, the regulatory environment, global access to information and markets, and the
ever-increasing pressure for new compounds put continuous pressure on pharmaceutical
manufacturers.
Healthcare companies are working harder to maintain the same profit margins they saw in the 1980s.
This has led many companies to look beyond traditional boundaries for ways of creating new value.Escalating cost pressures, directly influenced by managed care, integrated health systems and
employers, have been accompanied by demands for more services and value, such as supply chain
integration with disease management programs. The result squeezes profits. Meanwhile, as market
competition allows every player the ability to ‘choose the best at the best price’, management will
continue to concentrate on R&D, sales, and marketing, the drivers for increasing shareholder value.
Add to this scenario the increased financial pressures from more complex development cycles,
requiring greater capital investment for development launch and production, and the subsequently
reduced patent protection time. This makes it more difficult to recover capital investment. This is
the essence of the problem. The demand at one end of the value chain for increased investment in
R&D and at the other end for marketing to stay competitive draws capital away from the







 
NAME: DR. ANTHONY MELVIN CRASTO. 

Principal scientist, GLENMARK-GENERICS LTD

Navi mumbai, INDIA

Email  amcrasto@gmail.com

 

MOBILE+91-9323115463
TWITTER-   @amcrasto


web links
 




Anthony in different languages
  安东尼    Энтони    एंथनी  안토니   




manufacturing process itself.
In the face of these competing demands for scarce financial resources, companies have launched
rationalization initiatives. In some cases, excess manufacturing capacity has led companies to
generate spin-off facilities and business units, thus fueling the nascent contract manufacturing
market.
Until recently, this contract manufacturing market was fragmented and without clear leaders. Some
players have developed specialized skills, such as complex tableting or effervescents. BASF is an
example. But the market has been characterized by a large number of small suppliers, each with
limited capabilities and limited, if any, global coverage. There have also been problems of poor
compliance by some companies, and certain suppliers, spin-offs, and buy-outs from mergers were
often inflexible tailored to a limited number of products and technologies.
This contract market is now changing. Large pharmaceutical companies, having recognized the
problem are starting to cooperate to drive improvements in the supplier market. A number of
suppliers have recognized the opportunity and are trying to acquire critical mass in terms of
competence and volume. Specialty chemicals companies, for example, have come to see that a large
proportion of their products are commodities, with low margins and high sensitivity to the overall
business cycles.
With this new knowledge and vision, the chemical companies have begun to see themselves as life
science companies supplying active ingredients used by the large pharmaceuticals, and these are
companies with critical mass and global reach. The generic drug companies are another factor. For
them, partnerships with large pharmaceuticals may be an excellent fit in terms of core competence







for particular manufacturing operations.Benefits and advantages
As we noted earlier, the biotechnology companies have been among the earliest to adopt focused
sourcing strategies, not so much for strategic reasons, but rather because they have lacked the
necessary resources. The potential benefits they have seen could be realized by the large
pharmaceutical companies.




 

ANTHONY MELVIN CRASTO

THANKS AND REGARD'S
DR ANTHONY MELVIN CRASTO Ph.D

amcrasto@gmail.com

MOBILE-+91 9323115463
GLENMARK SCIENTIST ,  INDIA
web link
http://anthonycrasto.jimdo.com/
Congratulations! Your presentation titled "Anthony Crasto Glenmark scientist, helping millions with websites" has just crossed MILLION views.
アンソニー     安东尼   Энтони    안토니     أنتوني
join my process development group on google
you can post articles and will be administered by me on the google group which is very popular across the world